Corona Juan Carlos, Duchen Michael R
Department of Cell and Developmental Biology, University College London, London, WC1E 6BT, UK.
Neurochem Res. 2015 Feb;40(2):308-16. doi: 10.1007/s11064-014-1377-0. Epub 2014 Jul 10.
The peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPARγ was initially identified through its role in the regulation of glucose and lipid metabolism and cell differentiation. It also influences the expression or activity of a number of genes in a variety of signalling networks. These include regulation of redox balance, fatty acid oxidation, immune responses and mitochondrial function. Recent studies suggest that the PPARγ agonists may serve as good candidates for the treatment of several neurodegenerative disorders including Parkinson's disease (PD), Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis, even though multiple etiological factors contribute to the development of these disorders. Recent reports have also signposted a role for PPARγ coactivator-1α (PGC-1α) in several neurodegenerative disorders including PD. In this review, we explore the current knowledge of mechanisms underlying the beneficial effects of PPARγ agonists and PGC-1α in models of PD.
过氧化物酶体增殖物激活受体γ（PPARγ）是一种配体激活的转录因子，属于核激素受体超家族。PPARγ最初是通过其在调节葡萄糖和脂质代谢以及细胞分化中的作用而被鉴定出来的。它还影响多种信号网络中许多基因的表达或活性。这些包括氧化还原平衡的调节、脂肪酸氧化、免疫反应和线粒体功能。最近的研究表明，尽管多种病因因素导致这些疾病的发生，但PPARγ激动剂可能是治疗包括帕金森病（PD）、阿尔茨海默病、亨廷顿病和肌萎缩侧索硬化症在内的几种神经退行性疾病的良好候选药物。最近的报道也表明PPARγ共激活因子-1α（PGC-1α）在包括PD在内的几种神经退行性疾病中发挥作用。在这篇综述中，我们探讨了PPARγ激动剂和PGC-1α在PD模型中产生有益作用的潜在机制的现有知识。
